Company intelligence / Profile preview

Pathios Therapeutics

Abingdon/Milton Park, Oxfordshire, UKpathiostherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Pathios Therapeutics has advanced its lead program PTT‑4256—a first-in-class orally bioavailable small molecule inhibitor of GPR65—into early clinical development. Preclinical data show reversal of immunosuppression in the tumor microenvironment and single-agent anti-tumor efficacy in animal models. The company aims to address patients who do not respond to current immunotherapies by targeting the root cause of immune dysfunction within tumors.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small molecules (GPR65 inhibitors)
Industry: Biotech

Drug pipeline

2 assets

PTT-4256

1 more asset in the full pipeline.

Partnerships

St Vincent’s Institute (SVI) of Medical Research, MelbourneQueensland University of Technology (QUT), BrisbaneStrategic investment from Bristol Myers Squibb

Beyond the preview

Go deeper on Pathios Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathios Therapeutics.